Last reviewed · How we verify
NCT02541760
Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children
Phase 3 trial testing Monteleukast in Otitis Media With Effiusion in 143 participants. Completed in 1 April 2015.
1 March 2015
Quick facts
| Lead sponsor | Hormozgan University of Medical Sciences |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 143 |
| Start date | 1 April 2014 |
| Primary completion | 1 March 2015 |
| Estimated completion | 1 April 2015 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- Monteleukast — full drug profile →
- Mometasone — full drug profile →
Conditions studied
- Otitis Media With Effiusion — all drugs for Otitis Media With Effiusion →
Sponsor
Hormozgan University of Medical Sciences
Who can join
Adults 2 to 6, any sex, with Otitis Media With Effiusion. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Treatment response
Time frame: 1 months
Defined as complete, partial, or no response based on the physician examination
Sponsor's own description
Otitis media is one of the most common infections among children and is a complication in about 30% of common colds. The most common complication of acute otitis media is otitis media with effusion. Some studies have reported the effects of montelukast and mometasone nasal spray in treatment of otitis media with effusion. However, current information is inadequate in this issue. The aim of this study was to compare the effectiveness of montelukast and mometasone nasal spray in treatment of otitis media with effusion in children attending Koodakan hospital in Bandar Abbas, Iran.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial.
Rahmati MB, Safdarian F, Shiroui B, Zare S, et al · · 2017 · cited 2× · PMID 28894551 · DOI 10.19082/4890
Verify or expand the search:
- PubMed search for NCT02541760
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hormozgan University of Medical Sciences trials
Trials by the same sponsor.
- NCT06670573 — The Relationship Between Allergic Rhinitis, Forward Head Posture, and Anxiety Levels in Iranian Children · completed
- NCT06677684 — The Effect of Adjunct Vitamin a on Community-Acquired Pneumonia in Southern Iranian Children: a Randomized Clinical Tria · NA · completed
- NCT06665503 — The Impact of Zinc and Probiotics in Preventing Pediatric Antibiotic-Associated Diarrhea in Southern Iran · NA · completed
- NCT03266913 — Efficacy and Safety of Probiotics in Neonatal Hyperbilirubinemia · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02541760 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hormozgan University of Medical Sciences
- Last refreshed: 2 September 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02541760.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing